LLY vs VKTX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LLY and VKTX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LLY and VKTX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.

Full LLY guide

Viking Therapeutics (VKTX) is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Its highest-profile program is VK2735, a dual GLP-1 and GIP receptor agonist for obesity, being developed in both injectable and oral forms, which puts Viking among the most closely watched challengers in the booming weight-loss drug market dominated by Novo Nordisk and Eli Lilly. Viking is also developing VK2809, a thyroid-hormone receptor beta agonist for non-alcoholic steatohepatitis (NASH/MASH), VK0214 for a rare disease (X-linked adrenoleukodystrophy), and VK3019, an amylin receptor agonist. As a clinical-stage company, Viking has no approved products and generates no product revenue, funding itself from cash on its balance sheet. Headquartered in San Diego, California, VKTX is a speculative, binary biotech whose value hinges on clinical-trial outcomes and the eventual commercial path for its lead obesity drug.

Full VKTX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
• VKTX drivers: Lead obesity program (VK2735); Pipeline breadth in metabolic disease.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: LLY trades at a premium valuation (about 42x trailing and 27x forward earnings, and roughly 14x sales, as of October 2026), so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. For VKTX, viking is a clinical-stage biotech with no approved products and no product revenue, so it is highly speculative and potentially binary.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick LLY if you believe its drivers more; VKTX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LLY and VKTX guides.

LLY. At about $1,266 a share on October 16, 2026, Eli Lilly is valued near $1.13 trillion, roughly 42x trailing earnings and 27x the roughly $47.48 in EPS analysts expect for 2027. That premium rests on revenue growth near 48% in the latest quarter and margins (about 54% operating) that few drugmakers have reached. The debate centers on how large and durable the incretin market proves, how oral therapies such as Foundayo change it, and how Novo Nordisk and new entrants shape pricing; the October 29 third-quarter report (consensus about $7.16 EPS on $22.45 billion revenue) is the next data point.

VKTX. Viking has no earnings to value on a P/E basis; the stock is priced on the probability-weighted potential of its pipeline, above all VK2735 in obesity, and on acquisition speculation. At about $3.3 billion, the market is valuing two Phase 3 obesity programs at roughly $2.8 billion above cash, while analysts' targets imply far more. Cash runway matters because the annual loss now exceeds the cash balance, so additional fundraising could dilute holders. All figures are approximate and should be verified against current filings.

Headline figures (approximate, October 2026): LLY shows revenue (ttm) ~$79.7 billion, q2 2026 revenue ~$23.0 billion (up ~48% YoY), q2 2026 eps $8.38 vs ~$6.58 est., gross / operating margin (ttm) ~83% / ~54%; VKTX shows product revenue ~$0 (no approved products), net loss (ttm) ~$535 million; Q2 2026 ~$128 million, eps (q2 2026) -$1.10 vs -$1.21 consensus; Q3 consensus ~-$1.06, cash vs debt ~$502 million cash, ~$4 million debt (June 2026).

LLY and VKTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LLY and VKTX exposure against your real portfolio. It is not an investment adviser.